首页|麝香保心丸联合沙库巴曲缬沙坦对慢性心力衰竭患者心脏功能及炎症指标的影响

麝香保心丸联合沙库巴曲缬沙坦对慢性心力衰竭患者心脏功能及炎症指标的影响

扫码查看
目的 探究麝香保心丸联合沙库巴曲缬沙坦对慢性心力衰竭(CHF)患者心脏功能及炎症指标的影响.方法 选取2022年1月—2023年6月金乡县人民医院收治的100例CHF患者中为研究对象,按照随机数字表法将其分为对照组和观察组,各50例.对照组采用沙库巴曲缬沙坦治疗,观察组采用沙库巴曲缬沙坦联合麝香保心丸治疗.比较两组临床疗效、心脏功能指标、炎症指标及不良反应发生情况.结果 观察组治疗总有效率为96.00%,高于对照组的84.00%,差异有统计学意义(P<0.05).治疗后,观察组左心室射血分数(42.17±3.72)%及心输出量(6.16±1.06)L/min均高于对照组,左心室舒张末期内径(57.45±3.68)mm、左心室收缩末期内径(41.12±5.48)mm均短于对照组,白细胞介素-6水平(121.39±18.06)ng/L、C反应蛋白水平(24.34±5.13)mg/L及肿瘤坏死因子-a水平(105.27±15.44)pg/mL均低于对照组,组间差异有统计学意义(P<0.05).两组不良反应发生率比较,差异无统计学意义(P>0.05).结论 麝香保心丸联合沙库巴曲缬沙坦治疗CHF效果显著,可改善患者心功能,降低心脏炎症指标,且较为安全.
Effect of the Combination Therapy of Musk Heart Protecting Pill and Sacubitril Valsartan on Cardiac Function and Inflammatory Indicators in Patients with Chronic Heart Failure
Objective To investigate the effect of Musk Heart Protecting Pill combined with Sacubitril Valsartan on cardiac function and inflammatory indicators in patients with chronic heart failure (CHF). Methods 100 CHF patients admitted to Jinxiang County People's Hospital from January 2022 to June 2023 were selected as the research subjects,they were randomly divided into a control group and an observation group,with 50 patients in each group,using a random number table method. The control group was treated with Sacubitril Valsartan,while the observation group was treated with Sacubitril Valsartan combined with Musk Heart Protecting Pill. Compare the clinical efficacy,cardiac function indicators,inflammation indicators,and adverse reactions between two groups. Results The total effective rate of the observation group was 96.00%,which was higher than 84.00% of the control group,and the difference was statistically significant (P<0.05). After treatment,the left ventricular ejection fraction (42.17±3.72)% and cardiac output (6.16±1.06)L/min in the observation group were higher than those in the control group,the left ventricular end diastolic diameter (57.45±3.68)mm and left ventricular end systolic diameter (41.12±5.48) mm were shorter than those in the control group,the levels of interleukin-6 (121.39±18.06)ng/L,C-reactive protein (24.34±5.13) mg/L,and tumor necrosis factor-a (105.27±15.44)pg/mL were all lower than those in the control group,and the differences between the groups were statistically significant (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The combination of Musk Heart Protecting Pill and Sacubitril Valsartan has a significant effect on the treatment of CHF,which can improve patients' cardiac function,reduce cardiac inflammatory indicators,and is relatively safe.

Chronic heart failureSacubitril ValsartanMusk Heart Protecting PillCardiac functionInflammatory indicators

朱艾华

展开 >

金乡县人民医院心血管内科,山东济宁 272200

慢性心力衰竭 沙库巴曲缬沙坦 麝香保心丸 心脏功能 炎症指标

2024

反射疗法与康复医学

反射疗法与康复医学

ISSN:
年,卷(期):2024.5(18)